Figure 2.

Mean (SD) Plasma midazolam concentration–time profiles following two midazolam oral doses (2 mg) in the absence (day 1) and presence (day 16) of denosumab in postmenopausal women (Group A; n = 17*). * Of the 18 subjects who completed study treatment in Group A, 17 were included in pharmacokinetics parameter estimates and 1 was excluded because of prohibited medication use (diltiazem; see text).